Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatment
Abstract BRCA1/2 gene mutations, which result in a dysfunction of homologous recombination repair, have been discovered in at least 5% of breast cancer (BC) patients with the increase in BC incidence in recent years. PARP inhibitors (PARPis), the first drugs with clinical approval based on synthetic...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2023-04-01
|
| Series: | Interdisciplinary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/INMD.20220013 |